135 related articles for article (PubMed ID: 28744892)
1. Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution.
Hee SW; Parsons N; Stallard N
Biom J; 2018 Mar; 60(2):232-245. PubMed ID: 28744892
[TBL] [Abstract][Full Text] [Related]
2. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
3. Designing a series of decision-theoretic phase II trials in a small population.
Hee SW; Stallard N
Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
[TBL] [Abstract][Full Text] [Related]
4. Bayesian designs and the control of frequentist characteristics: a practical solution.
Ventz S; Trippa L
Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
[TBL] [Abstract][Full Text] [Related]
5. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
7. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
8. Decision theoretic designs for phase II clinical trials with multiple outcomes.
Stallard N; Thall PF; Whitehead J
Biometrics; 1999 Sep; 55(3):971-7. PubMed ID: 11315037
[TBL] [Abstract][Full Text] [Related]
9. Bayesian randomized clinical trials: From fixed to adaptive design.
Yin G; Lam CK; Shi H
Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
[TBL] [Abstract][Full Text] [Related]
10. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
[TBL] [Abstract][Full Text] [Related]
11. Approaches for optimal sequential decision analysis in clinical trials.
Carlin BP; Kadane JB; Gelfand AE
Biometrics; 1998 Sep; 54(3):964-75. PubMed ID: 9750245
[TBL] [Abstract][Full Text] [Related]
12. Bayesian hypothesis testing in two-arm trials with dichotomous outcomes.
Zaslavsky BG
Biometrics; 2013 Mar; 69(1):157-63. PubMed ID: 23002906
[TBL] [Abstract][Full Text] [Related]
13. Implementing a decision-theoretic design in clinical trials: why and how?
Palmer CR; Shahumyan H
Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
[TBL] [Abstract][Full Text] [Related]
14. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
15. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
16. An adaptive approach to implementing bivariate group sequential clinical trial designs.
Todd S
J Biopharm Stat; 2003 Nov; 13(4):605-19. PubMed ID: 14584711
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian decision-theoretic sequential response-adaptive randomization design.
Jiang F; Jack Lee J; Müller P
Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
[TBL] [Abstract][Full Text] [Related]
18. The Performance of Fixed-Horizon, Look-Ahead Procedures Compared to Backward Induction in Bayesian Adaptive-Randomization Decision-Theoretic Clinical Trial Design.
Lipsky AM; Lewis RJ
Int J Biostat; 2019 Feb; 15(1):. PubMed ID: 30726189
[TBL] [Abstract][Full Text] [Related]
19. Optimal choice of the number of treatments to be included in a clinical trial.
Stallard N; Posch M; Friede T; Koenig F; Brannath W
Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
[TBL] [Abstract][Full Text] [Related]
20. Screening designs for drug development.
Rossell D; Müller P; Rosner GL
Biostatistics; 2007 Jul; 8(3):595-608. PubMed ID: 17030589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
